Jump to main content

First Gene Therapy for Hemophilia B, CSL’s HEMGENIX®, Approved by the European Commission

Approval of HEMGENIX® underscores CSL’s promise to deliver life-changing innovations that have the potential to help patients lead full lives.


Global biotechnology leader CSL today announced that the European Commission has granted conditional marketing authorization (CMA) for HEMGENIX® (etranacogene dezaparvovec).